Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 9/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 6/20 | 0.55 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.54 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.54 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.54 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864297 | 0.80 | HDAC8 (0.58) | CES1HDAC8FAAHHDAC1HDAC2 | |
| SCHEMBL7366770 | 0.78 | HDAC1 (0.65) | CES1HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL4838333 | 0.75 | CES1 (1.00) | CES1FAAHSMN1; SMN2NCEH1 | |
| SCHEMBL864213 | 0.75 | LIPG (0.49) | HDAC8HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL10102734 | 0.75 | HDAC8 (0.65) | CES1HDAC8FAAHHDAC1HDAC2 | |
| SCHEMBL14499473 | 0.73 | NPC1 (0.60) | CES1HDAC8FAAHHDAC1HDAC2 | |
| SCHEMBL14499477 | 0.73 | NPC1 (0.60) | CES1HDAC8FAAHHDAC1HDAC2 | |
| SCHEMBL14499481 | 0.73 | NPC1 (0.60) | CES1HDAC8FAAHHDAC1HDAC2 | |
| SCHEMBL18220915 | 0.72 | HDAC8 (0.58) | CES1HDAC8FAAHHDAC1HDAC2 | |
| SCHEMBL14499470 | 0.72 | NPC1 (0.61) | CES1HDAC8FAAHHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621278-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-07 | — | — | EP | disclosed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | disclosed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | disclosed |
| WO-2012047580-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | WO | disclosed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | LIPG, LIPA, LIPE | CES1 8/4885HDAC8 438/4885FAAH 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.